about
Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and BeyondGenomes2Drugs: identifies target proteins and lead drugs from proteome dataNovel anti-staphylococcal and anti-biofilm properties of two anti-malarial compounds: MMV665953 {1-(3-chloro-4-fluorophenyl)-3-(3,4-dichlorophenyl)urea} and MMV665807 {5-chloro-2-hydroxy-N-[3-(trifluoromethyl)phenyl]benzamide}.Molecular interactions and inhibition of the staphylococcal biofilm-forming protein SdrCTIN-a combinatorial compound collection of synthetically feasible multicomponent synthesis products.Roles for fibrinogen, immunoglobulin and complement in platelet activation promoted by Staphylococcus aureus clumping factor A.Integrins as therapeutic targets: lessons and opportunities.The therapeutic potential of I-domain integrins.A novel platinum complex of the histone deacetylase inhibitor belinostat: rational design, development and in vitro cytotoxicity.Both complement- and fibrinogen-dependent mechanisms contribute to platelet aggregation mediated by Staphylococcus aureus clumping factor B.In vitro activities of synthetic host defense propeptides processed by neutrophil elastase against cystic fibrosis pathogensElucidating the role of Staphylococcus epidermidis serine-aspartate repeat protein G in platelet activation.Deadly Engagement: FcγRIIa-Antibody Interaction is Key in Sepsis.A novel role for the fibrinogen Asn-Gly-Arg (NGR) motif in platelet function.C-reactive protein binds to αIIbβ3Fibrinogen and elastin bind to the same region within the A domain of fibronectin binding protein A, an MSCRAMM of Staphylococcus aureusFibronectin-binding proteins of Staphylococcus aureus mediate activation of human platelets via fibrinogen and fibronectin bridges to integrin GPIIb/IIIa and IgG binding to the FcgammaRIIa receptor
P50
Q27826351-24FB6311-58E1-42F3-ADC2-C3272D259B0FQ28475728-BE3B38EC-2ACE-49A5-98F8-B7627CBB5E2CQ30491192-9F9FC829-509B-4CFA-89E6-55D6CFF964EAQ33556800-87F608BD-127D-4FAF-959A-A266FFE6F67FQ33874102-83FB86A3-80D5-4EF9-BA97-280F976B0062Q33988923-A7033F5B-42F1-419F-9F65-C09A3237A525Q37795552-E375FEF7-CE70-48AD-BE93-BED4D70E5F8AQ38229351-1D9A3EFB-E237-4676-8E8A-0942F199DC1AQ39163083-03BC93D3-F7C5-45BD-9233-259D85668751Q41861048-E585EED5-0747-43D1-AA83-CCF704CC1CE5Q42058965-158BD895-8604-4013-93F0-346AEABBD2B7Q45987820-A8B0F3A5-6C6D-4E7B-86D8-B9F0AD31FA9BQ50212505-3BB4ADED-64F3-468C-86EA-4C81049B6F1AQ50445636-563A7519-69E2-4FFE-8AE3-DF7BACBC55B0Q58977876-0AA2ACEC-C7C9-4B6E-BE51-820FBE972FA1Q58977881-B6489DAB-72CE-4296-8DAC-645AAD8177EBQ58977886-6F2A4E78-9A9F-4D64-90FD-A1B62AE4C3B7
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Marian Brennan
@ast
Marian Brennan
@en
Marian Brennan
@es
Marian Brennan
@nl
Marian Brennan
@sl
type
label
Marian Brennan
@ast
Marian Brennan
@en
Marian Brennan
@es
Marian Brennan
@nl
Marian Brennan
@sl
prefLabel
Marian Brennan
@ast
Marian Brennan
@en
Marian Brennan
@es
Marian Brennan
@nl
Marian Brennan
@sl
P1053
D-7564-2013
P106
P21
P31
P3829
P496
0000-0003-2368-5383